Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy

Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA

IgA nephropathy accounts for about 45 per cent of primary glomerular diseases in China and about 26 per cent of renal biopsies in patients with chronic failure.According to current guideline recommendations, there are limited indications for non-steroidal MRAs. Therefore clinical studies to explore the range of clinical indications for fenetyllone are warranted.

Primary IgA nephropathy (IgAN) is an immunopathological diagnostic term for a type of glomerulonephritis characterised by the deposition of IgA or IgA-dominant immune complexes in the glomerular tunica albuginea. And in China IgA nephropathy accounts for about 45% of primary glomerular diseases and about 26% of renal biopsies in patients with chronic failure. Among them, about 15-40% of IgA nephropathy patients progress to renal failure after 10-20 years; IgA nephropathy has become one of the main causes of end-stage renal failure.The nonsteroidal salicorticoid receptor antagonist (MRA)- finerenone reduces the risk of composite renal outcomes, ESKD, or renal death in patients with type 2 diabetes and CKD.There are limited indications for non-steroidal MRAs. Therefore clinical studies to explore the range of clinical indications for fenetyllone are warranted.

Inclusion Criteria:

• primary IgAN diagnosed by renal biopsy;
• receive RASI inhibitors for at least 3 months;
• serum potassium <5 mmol/L;
• protein-to-creatinine ratio (PCR) >0.3 mg/g

Exclusion Criteria:

• secondary IgAN;
• autosomal dominant polycystic kidney disease or autosomal recessive polycystic kidney disease, lupus nephritis, lupus nephritis,;
• previous renal transplantation;
• chronic hepatic disease, malignant tumor, active malignancy, heart failure with ejection fraction <40%;
• followed up less than 6 months;